DK2069324T3 - Fusioneret aminopyridin som hsp90-inhibitorer - Google Patents

Fusioneret aminopyridin som hsp90-inhibitorer

Info

Publication number
DK2069324T3
DK2069324T3 DK08743755.4T DK08743755T DK2069324T3 DK 2069324 T3 DK2069324 T3 DK 2069324T3 DK 08743755 T DK08743755 T DK 08743755T DK 2069324 T3 DK2069324 T3 DK 2069324T3
Authority
DK
Denmark
Prior art keywords
aminopyridine
fused
hsp90 inhibitors
hsp90
inhibitors
Prior art date
Application number
DK08743755.4T
Other languages
Danish (da)
English (en)
Inventor
Xiong Cai
Changgeng Qian
Haixiao Zhai
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DK2069324T3 publication Critical patent/DK2069324T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK08743755.4T 2007-03-20 2008-03-10 Fusioneret aminopyridin som hsp90-inhibitorer DK2069324T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89592107P 2007-03-20 2007-03-20
US1528807P 2007-12-20 2007-12-20
PCT/US2008/056396 WO2008115719A1 (en) 2007-03-20 2008-03-10 Fused amino pyridine as hsp90 inhibitors

Publications (1)

Publication Number Publication Date
DK2069324T3 true DK2069324T3 (da) 2013-09-02

Family

ID=39766345

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08743755.4T DK2069324T3 (da) 2007-03-20 2008-03-10 Fusioneret aminopyridin som hsp90-inhibitorer

Country Status (24)

Country Link
US (10) US8324240B2 (enExample)
EP (1) EP2069324B1 (enExample)
JP (1) JP5401329B2 (enExample)
KR (1) KR101313804B1 (enExample)
CN (1) CN101679347B (enExample)
AU (1) AU2008229216B2 (enExample)
BR (1) BRPI0808301B1 (enExample)
CA (1) CA2680778C (enExample)
CY (1) CY1114507T1 (enExample)
DK (1) DK2069324T3 (enExample)
EA (1) EA019103B1 (enExample)
ES (1) ES2430217T3 (enExample)
HR (1) HRP20130910T1 (enExample)
IL (2) IL200924A (enExample)
MX (1) MX2009009936A (enExample)
MY (1) MY148860A (enExample)
NZ (1) NZ579635A (enExample)
PL (1) PL2069324T3 (enExample)
PT (1) PT2069324E (enExample)
RS (1) RS52978B (enExample)
SI (1) SI2069324T1 (enExample)
TW (1) TWI471131B (enExample)
WO (1) WO2008115719A1 (enExample)
ZA (1) ZA200906371B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
WO2006084030A2 (en) * 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
KR20090077914A (ko) * 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 항증식제로서의 다작용성 소분자
MX2009009936A (es) * 2007-03-20 2010-02-11 Curis Inc Amino piridina fusionada como inhibidores de hsp90.
WO2008115262A2 (en) * 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
EP2469399B1 (en) 2008-02-11 2019-09-11 Idean Enterprises Oy Layer-based user interface
US8017780B1 (en) 2008-10-09 2011-09-13 Myrexis, Inc. Therapeutic compounds and uses thereof
US8722703B2 (en) 2009-01-16 2014-05-13 Curis, Inc. Fused amino pyridines for the treatment of brain tumors
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
MX2012000487A (es) * 2009-07-10 2012-01-27 Taiho Pharmaceutical Co Ltd Compuesto de azabiciclo, y sal del mismo.
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011044394A1 (en) * 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
AU2013204109B2 (en) * 2009-10-07 2016-05-05 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
US20110217288A1 (en) * 2010-03-05 2011-09-08 Baylor Research Institute Involvement of Androgen/Androgen Receptor Pathway in Fabry Disease
WO2012131413A1 (en) 2011-03-25 2012-10-04 Debiopharm Sa Crystalline forms of fused amino pyridines as hsp90 inhibitors
WO2012138894A1 (en) 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
EP2694506B1 (en) * 2011-04-05 2017-09-20 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
ES2630102T3 (es) * 2011-04-26 2017-08-18 Rdd Pharma Ltd. Oximetazolina para el tratamiento de trastornos ano-rectales
CN104271587B (zh) 2012-02-09 2017-09-12 堪萨斯大学 Hsp90C端抑制剂
KR20150010793A (ko) 2012-05-25 2015-01-28 버그 엘엘씨 열 충격 단백질 (hsp) 90-베타의 조절에 의한 대사 증후군의 치료 방법들
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
TW201533043A (zh) * 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
HK1226063A1 (zh) * 2013-08-16 2017-09-22 Memorial Sloan-Kettering Cancer Center 选择性grp94抑制剂和其用途
KR102325454B1 (ko) 2013-12-23 2021-11-16 메모리얼 슬로안 케터링 캔서 센터 방사성표지화를 위한 방법 및 시약
EP3152307A4 (en) 2014-06-06 2018-05-02 Berg LLC Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
CA3289739A1 (en) 2014-06-24 2025-11-29 The Univ Of Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
BR112017005313A2 (pt) 2014-09-17 2017-12-05 Memorial Sloan Kettering Cancer Center formação de imagem e terapia para inflamação e infecção direcionadas por hsp90
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
PL3319959T3 (pl) 2015-07-06 2022-02-14 Alkermes, Inc. Hetero-haloinhibitory deacetylazy histonowej
BR112019014235A2 (pt) 2017-01-11 2020-03-17 Rodin Therapeutics, Inc. Inibidores bicíclicos de histona desacetilase
SMT201900517T1 (it) 2017-03-20 2019-11-13 Forma Therapeutics Inc Composizioni di pirrolopirrolo come attivatori di piruvato chinasi (pkr)
US20200114022A1 (en) * 2017-03-31 2020-04-16 Alma Bio Therapeutics Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same
CA3071861A1 (en) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11827664B2 (en) 2018-05-14 2023-11-28 Reata Pharmaceuticals, Inc Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
US11001588B2 (en) 2018-09-19 2021-05-11 Forma Therapeutics, Inc. Activating pyruvate kinase R and mutants thereof
JP7532385B2 (ja) 2019-01-31 2024-08-13 杏林製薬株式会社 １５－ｐｇｄｈ阻害薬
MX2022003254A (es) 2019-09-19 2022-04-18 Forma Therapeutics Inc Composiciones activadoras de piruvato cinasa r (pkr).
GB202006382D0 (en) 2020-04-30 2020-06-17 Spermatech As Use
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023006993A1 (en) 2021-07-30 2023-02-02 Atmosr Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome
JP2025533648A (ja) * 2022-10-06 2025-10-07 レグラニオン、エルエルシー 化膿性汗腺炎を治療するための方法および組成物
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025014551A1 (en) * 2023-07-10 2025-01-16 Regranion, Llc Methods and compositions for treating atopic dermatitis
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080645A1 (en) * 2023-10-10 2025-04-17 Regranion, Llc Methods and compositions for treating bullous pemphigoid
WO2025080629A1 (en) * 2023-10-10 2025-04-17 Regranion, Llc Methods and compositions for treating behçet's disease
WO2025080623A1 (en) * 2023-10-10 2025-04-17 Regranion, Llc Methods and compositions for treating discoid lupus erythematosus, systemic lupus erythematosus, and subacute cutaneous lupus erythematosus
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217284A1 (en) * 2024-04-09 2025-10-16 Regranion, Llc Methods and compositions for treating inflammatory and autoimmune disorders of the skin
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ288182B6 (en) 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US5644063A (en) * 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US6723727B1 (en) * 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
BR9907300A (pt) * 1998-01-27 2000-10-24 Aventis Pharm Prod Inc Inibidores do fator xa oxoaza-heterociclila substituìdos
AU2381600A (en) * 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
CN1166666C (zh) * 1999-07-02 2004-09-15 卫材株式会社 缩合咪唑化合物和治疗糖尿病的药物
EP1208097B1 (en) * 1999-07-28 2009-02-18 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
AU2877102A (en) 2000-11-02 2002-05-15 Sloan Kettering Inst Cancer Small molecule compositions for binding to hsp90
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
EP1440072A4 (en) * 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
US7189723B2 (en) * 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
EP1608628A2 (en) * 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN1816530A (zh) * 2003-07-01 2006-08-09 麦克公司 用于治疗高眼压症的眼用组合物
NZ546611A (en) * 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
EP1669350B1 (en) 2003-09-22 2012-02-29 Msd K.K. Piperidine derivatives
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20070259881A1 (en) * 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
WO2006029115A2 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006084030A2 (en) * 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
AU2006239632B2 (en) * 2005-04-25 2012-03-15 Merck Patent Gmbh Novel AZA- heterocycles serving as kinase inhibitors
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
WO2007075572A2 (en) * 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
WO2007092496A2 (en) * 2006-02-07 2007-08-16 Conforma Therapeutics Corporation 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
KR20080085232A (ko) 2006-02-17 2008-09-23 화이자 리미티드 Ｔｌｒ7 조절제로서 3-데아자퓨린 유도체
US7595401B2 (en) * 2006-05-12 2009-09-29 Myriad Pharmaceuticals, Inc. Therapeutic compounds and their use in cancer
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
KR20090077914A (ko) * 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 항증식제로서의 다작용성 소분자
CA2667826C (en) 2006-10-28 2013-10-08 Methylgene Inc. Inhibitors of histone deacetylase
WO2008115262A2 (en) * 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
MX2009009936A (es) * 2007-03-20 2010-02-11 Curis Inc Amino piridina fusionada como inhibidores de hsp90.
US8722703B2 (en) 2009-01-16 2014-05-13 Curis, Inc. Fused amino pyridines for the treatment of brain tumors

Also Published As

Publication number Publication date
EA200901263A1 (ru) 2010-02-26
ZA200906371B (en) 2010-05-26
AU2008229216B2 (en) 2013-03-21
AU2008229216A1 (en) 2008-09-25
US20190010152A1 (en) 2019-01-10
KR101313804B1 (ko) 2013-10-01
WO2008115719A9 (en) 2009-02-26
RS52978B (sr) 2014-02-28
US9402832B2 (en) 2016-08-02
US9630965B2 (en) 2017-04-25
CN101679347A (zh) 2010-03-24
JP5401329B2 (ja) 2014-01-29
US9040556B2 (en) 2015-05-26
US11560377B2 (en) 2023-01-24
HRP20130910T1 (hr) 2013-10-25
US20230192687A1 (en) 2023-06-22
EP2069324A1 (en) 2009-06-17
IL236938A0 (en) 2015-03-31
EA019103B1 (ru) 2014-01-30
US10844056B2 (en) 2020-11-24
MX2009009936A (es) 2010-02-11
US20160058742A1 (en) 2016-03-03
TW200845967A (en) 2008-12-01
US20170267674A1 (en) 2017-09-21
SI2069324T1 (sl) 2013-10-30
US20200062754A1 (en) 2020-02-27
PT2069324E (pt) 2013-10-10
KR20100015739A (ko) 2010-02-12
PL2069324T3 (pl) 2014-01-31
US20140221343A1 (en) 2014-08-07
US20170002002A1 (en) 2017-01-05
CA2680778C (en) 2016-05-10
NZ579635A (en) 2011-07-29
BRPI0808301A2 (pt) 2013-08-06
EP2069324B1 (en) 2013-07-31
WO2008115719A1 (en) 2008-09-25
US10035797B2 (en) 2018-07-31
US8324240B2 (en) 2012-12-04
IL200924A (en) 2015-02-26
TWI471131B (zh) 2015-02-01
CA2680778A1 (en) 2008-09-25
MY148860A (en) 2013-06-14
HK1131986A1 (en) 2010-02-12
US8586605B2 (en) 2013-11-19
US20210292317A1 (en) 2021-09-23
BRPI0808301B1 (pt) 2022-05-03
US20080234314A1 (en) 2008-09-25
EP2069324A4 (en) 2011-09-07
ES2430217T3 (es) 2013-11-19
CY1114507T1 (el) 2016-10-05
CN101679347B (zh) 2014-10-22
US20120237508A1 (en) 2012-09-20
JP2010522184A (ja) 2010-07-01
IL200924A0 (en) 2010-05-17
US10428068B2 (en) 2019-10-01

Similar Documents

Publication Publication Date Title
DK2069324T3 (da) Fusioneret aminopyridin som hsp90-inhibitorer
DK2139892T3 (da) Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
CY2017016I2 (el) Αναστολεις πρωτεασωματος
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2162131T3 (da) Quinolin-derivativer som pi3-kinase-inhibitorer
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
DK2300465T3 (da) Imidazopyridinderivater som hæmmere af receptortyrosinkinaser
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
BRPI0813836A2 (pt) Derivados pirazólicos
BRPI0814359A2 (pt) Método
BRPI0817226A2 (pt) Método
BRPI0817726A2 (pt) Método
HUE056966T2 (hu) Horonymarási eljárás
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
DK2383271T3 (da) Aminoquinoloner som GSK-3-inhibitorer
ATE518837T1 (de) Indazolamidderivate
DK2078001T3 (da) Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer
EP2197705A4 (en) REAR-VIEW MIRROR
DK2152370T3 (da) Aryletherpyridazinonderivater
FI20075851A0 (fi) Muodostusosa
DK2252609T3 (da) Pyridin-2-yl-derivater som immunomodulerende midler
ATE519760T1 (de) Isoxazolimidazolderivate
BRPI0809678A2 (pt) Métodos